ADNI Dataset

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer’s disease (AD).[1] This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment.[2] Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers.[2][3] This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact,[4]
firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers,[4] and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide.[5] To date, over 1000 scientific publications have used ADNI data.[6] A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model.[4] ADNI has been running since 2004 and is currently funded until 2021.[7]

Source: Wikipedia, https://en.wikipedia.org/wiki/Alzheimer%27s_Disease_Neuroimaging_Initiative

阿尔茨海默病神经影像学倡议（ADNI）是一项多中心研究，旨在提升阿尔茨海默病（AD）的预防和治疗临床试验。该合作研究汇集了私营和公共部门的专长与资金，以研究患有AD的受试者、可能发展为AD的个体以及无认知障碍迹象的对照组。[1] 美国和加拿大63个研究点的科研人员利用神经影像学、生化及遗传生物学标志追踪人类大脑中AD的进展。[2][3] 此项知识有助于发现更优的临床试验，以预防和治疗AD。ADNI在全球范围内产生了深远影响，首先是通过制定一套标准化协议，允许多个中心结果的比较。[4] 其次，通过其数据共享政策，向全球合格研究人员无限制地提供所有数据。[5] 迄今为止，已有超过1000篇科学出版物使用了ADNI数据。[6] 基于ADNI作为模型的多个与AD及其他疾病相关的倡议已被设计和实施。[4] ADNI自2004年起运行，目前资金支持将持续至2021年。[7] 来源：维基百科，https://en.wikipedia.org/wiki/Alzheimer%27s_Disease_Neuroimaging_Initiative